The Financial Horizons
No Result
View All Result
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Latest News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
  • Latest News
No Result
View All Result
The Financial Horizons
No Result
View All Result
Home Economy

Hims Stock Soared 8.87% Last Week: Should You Invest?

by
July 31, 2024
in Economy
0
Hims Stock Soared 8.87% Last Week: Should You Invest?
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Hims Stock Soared By 8.87% Last Week. Should You Buy?

Making good investment decisions is paramount for achieving success in the financial markets. Some stocks seem like fine opportunities, but ultimately, they prove to be wrong choices. On the other hand, others aren’t so lauded, but they bring hefty profits to the traders. Which category does the Hims Stock belong to? What is its potential for growth? And should you purchase these shares now or not?

Hims & Hers Health, Inc., the company behind this stock, provides healthcare platforms. People seeking to improve their health and wellness often use its website for its numerous advantages.

The company enables customers to get access to a provider network. It also offers a cloud pharmacy, an electronic medical record system, and digital prescriptions. Additionally, people can receive treatment for various conditions, such as acne, hair loss, sexual health concerns, and mental health issues, as well as support for weight loss.

The Hims & Hers platform serves as an intermediary between patients and licensed healthcare professionals, who can prescribe medications if needed. Customers can also purchase various healthcare and wellness products on the website.

Additionally, the Hims & Hers mobile application provides users with access to educational programs and various other healthcare-related services.

The platform has a vast and growing community of users, which translates to substantial income from fees and sales. As a result, the stock price has been soaring for the past several months.

How Is Hims Faring Now?

The Hims stock has experienced occasional fluctuations but has traded mainly in bullish territory. Moreover, its market capitalisation recently reached almost $4.66 billion. The company’s revenue hit $959.40 million, according to the latest reports. These figures, along with the shares’ upward trajectory, have bolstered the popularity of Hims & Hers stock in the market.

The shares exchanged hands at $21.71 on Monday, declining slightly during the last session. However, over the last quarter, the company experienced substantial insider buying. This indicates that the individuals who know the inner workings of the firm have faith in it and expect further growth.

The stock price experienced high volatility. At one point, it even plunged by 64.5% compared to its estimated fair value. However, some analysts believe that its revenue will grow exponentially in the coming months and years.

What Is The Hims Stock Forecast?

Some of the top analysts forecast Hims’ earnings to grow by 40.32% per year. Moreover, they think the revenue will increase by 18.5% in the same period of time.

Analyst recommendations are based on technical analysis, earnings reports, average returns, and market factors. When they suggest Hims & Hers stock could outperform the US market average, there’s a real possibility. The company is also expanding its products and platform while improving leadership to ensure smooth operations.

As a result, this stock currently has a buy rating, attracting many traders. However, despite this positive news, some experts believe Hims’ trajectory may change soon. Last week, its price soared by 8.57% before starting to trade in the red on Monday.

If Everything’s Alright, Why Is Hims Stock Going Down?

Analysts warn that Hims is currently overvalued due to the long bull run. So, the price might decrease in the coming months, especially if investor interest wanes.

On Tuesday, Glen Santangelo of Jefferies downgraded his recommendation for these shares. He previously ranked the stock a buy but has now moved his rating to hold. Moreover, he cut his price target from $17 to $15.

According to Santangelo, Hims & Hers showed solid performance, but it’s overvalued now. He advises investors to wait until the shares’ price decreases and buy the stock after that.

Still, other analysts predict that the stock price will increase over the next decade. For 2030, they estimate that Hims value will reach $33.10, but only if the stock continues growing with its current 10-year average growth rate.

On the other hand, it’s still possible and even expected that the stock will lose some of its overpriced winnings before it continues growing at a more adequate rate. So, investors should follow the stock market news and Hims’ developments and wait until its price drops before buying it.

The post Hims Stock Soared 8.87% Last Week: Should You Invest? appeared first on FinanceBrokerage.

Previous Post

AI ETFs – A New Way For Conquering the Financial World!

Next Post

EURUSD and GBPUSD: The Euro could rise to the 1.08500 level

Next Post
EURUSD and GBPUSD: The Euro could rise to the 1.08500 level

EURUSD and GBPUSD: The Euro could rise to the 1.08500 level

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    Homeless people can be removed from streets by cities, states in new Trump executive order

    Homeless people can be removed from streets by cities, states in new Trump executive order

    July 24, 2025
    Alphabet beats earnings expectations, raises spending forecast

    Alphabet beats earnings expectations, raises spending forecast

    July 24, 2025
    Uber will let women drivers and riders request to avoid being paired with men

    Uber will let women drivers and riders request to avoid being paired with men

    July 24, 2025
    UnitedHealth says it faces DOJ investigation over Medicare billing practices

    UnitedHealth says it faces DOJ investigation over Medicare billing practices

    July 24, 2025
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: Thefinancialhorizons.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thefinancialhorizons.com | All Rights Reserved

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Editor’s Pick
    • Latest News

    Disclaimer: Thefinancialhorizons.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 thefinancialhorizons.com | All Rights Reserved